Actively Recruiting

Early Phase 1
Age: 18Years +
All Genders
NCT06613841

Multitracer [18F]Fluciclovine and 18F-FDG PET, and Advanced MRI for Metabolic Profiling of Glioblastoma

Led by Abramson Cancer Center at Penn Medicine · Updated on 2025-11-28

15

Participants Needed

2

Research Sites

87 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

* To perform metabolic phenotyping of treatment naïve and recurrent GBM by multitracer \[18F\]Fluciclovine and 18F-FDG PET. * To compare uptake measures of 18F-Fluciclovine and 18F-FDG and MRI quantification of glutamate and lactate levels to tumor tissue laboratory assays (RNA seq and proteomics) of glutamine/glutamate, glucose, and lactate metabolism. * To perform metabolic phenotyping of treatment naïve and recurrent GBM by advanced MRI methods at 7 Tesla

CONDITIONS

Official Title

Multitracer [18F]Fluciclovine and 18F-FDG PET, and Advanced MRI for Metabolic Profiling of Glioblastoma

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Participants 18 years of age or older
  • Diagnosis of a new intra-axial brain mass consistent with glioblastoma as confirmed by a neuroradiologist
  • OR new or increased contrast-enhancing lesion(s) in patients with prior histologic or molecular diagnosis of glioblastoma after treatment
  • Recommended for surgical tumor removal
  • Life expectancy greater than 3 months as judged by a physician
  • Karnofsky performance status of 60 or higher
  • Willing and able to provide informed consent according to institutional and federal guidelines
Not Eligible

You will not qualify if you...

  • Unable to tolerate imaging procedures as determined by physician
  • Pregnant or breastfeeding females at screening (pregnancy test required for women of childbearing potential)
  • Any medical condition or illness that could compromise safety or participation as judged by a physician
  • Contraindications to MRI
  • Individuals unable to understand or provide informed consent

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 2 locations

1

Hospital of the University of Pennsylvania

Philadelphia, Pennsylvania, United States, 19104

Actively Recruiting

2

University of Pennsylvania

Philadelphia, Pennsylvania, United States, 19104

Actively Recruiting

Loading map...

Research Team

L

Leeanne Lezotte

CONTACT

J

Jeremy T Westerman, B.S.

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

DIAGNOSTIC

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here